Peer-reviewedCC BY-NC 4.0Dermatology and Therapy
Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis)
28 affiliations
- 1Departmental Faculty of Medicine UniCamillus-Saint Camillus International, University of Health and Medical Sciences, Rome, Italy
- 2Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
- 3Department of Clinical Medicine, Internal Medicine Unit With Rheumatology, Dermatology, Diabetology and Tertiary Diabetic Foot Health-Care, National Relevance and High Specialization Hospital Trust ARNAS Civico, Di Cristina, Benfratelli, Palermo, Italy
- 4Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties [PROMISE], University of Palermo, Palermo, Italy
- 5Department of Medical Science, Dermatology Clinic, University of Turin, Turin, Italy
- 6Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy
- 7Department of Dermatology, Dipartimento di Scienze Della Salute (DISSal), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 8Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy
- 9Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy
- 10Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan Italy
- 11Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
- 12Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- 13Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
- 14Department of Medical and Surgical Sciences Alma Mater, Studiorum University of Bologna, Bologna, Italy
- 15Dermatological Clinic, Department of Specialized Medicine, University of Modena, Modena, Italy
- 16Department of Clinical and Molecular Sciences-Dermatological Clinic, Università Politecnica Delle Marche, Ancona, Italy
- 17Dermatology Unit, Department of Clinical and Experimental Medicine, Ospedale Santa Chiara, Pisa, Italy
- 18Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy
- 19Dermatology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy
- 20Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
- 21Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
- 22Dermatology Unit, Department of Medical and Cardiovascular Sciences, University of “La Sapienza”, Rome, Italy
- 23Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Palermo, Italy
- 24Section of Dermatology, Italian Neurotraumatology Institute (I.N.I.), Grottaferrata, Italy
- 25Department of Biomedical, Dental Sciences and Morphofunctional Imaging (BIOMORF), University of Messina, Messina, Italy
- 26Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari “Aldo Moro”, Bari, Italy
- 27Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy
- 28U.O.S.D. Dermatologica-Centro per la Cura della Psoriasi, Ospedale Perrino, Brindisi, Italy
Abstract
Introduction: Conventional Psoriasis Area and Severity Index (PASI) response rates provide a cross-sectional assessment of treatment effectiveness but do not capture the speed, magnitude, and persistence of clinical improvement. This study evaluated the patient-level cumulative clinical benefit of brodalumab over 52 weeks in routine clinical practice.
Methods: This multicentre, retrospective, observational study included adults with moderate-to-severe plaque psoriasis treated with brodalumab within the Italian Landscape Psoriasis database. The primary analysis included patients with PASI assessments at baseline and Weeks 16, 32, and 52. Individual percentage PASI improvement trajectories were integrated using the trapezoidal area under the curve and expressed as normalized cumulative clinical benefit and clearance-equivalent days. Baseline factors associated with cumulative benefit were assessed using multivariable median quantile regression.
Results: Among 858 patients eligible for the 52-week analysis, 764 had complete longitudinal PASI data, and 645 were included in the multivariable analysis. Median PASI decreased from 14.7 at baseline to 0.0 at Weeks 16, 32, and 52. At Week 52, 93.1%, 86.1%, and 70.4% of patients achieved PASI 75, PASI 90, and PASI 100, respectively. Median normalized cumulative clinical benefit was 97.4% (interquartile range, 90.0–100.0), corresponding to 300.0 clearance-equivalent days (277.2–308.0). Palmoplantar involvement was independently associated with lower cumulative benefit (adjusted median difference, − 3.21 percentage points; 95% confidence interval, − 6.29 to − 0.87), whereas scalp or facial involvement was associated with modestly higher benefit (+ 1.39; 0.38–3.27). Longer psoriasis duration was associated with a small increase in cumulative benefit.
Conclusion: Brodalumab provided rapid, deep, and sustained disease control over 52 weeks. Patient-level cumulative outcomes may complement conventional PASI response rates by capturing the overall longitudinal treatment benefit.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13555-026-01925-5.
Related
- Clinical Outcomes Following Mandatory Switching to an Adalimumab Biosimilar in Patients with Psoriasis: A Real-world Single-centre Experience.
- Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives
- Efficacy of sound therapy in chronic tinnitus patients with mild hearing loss: a multicentre, double-blind, placebo-controlled randomized clinical trial
- Clinical practice guideline for psoriasis management in Latin America
- Risankizumab in Psoriasis: Real-World Effectiveness, Safety, and Clinical Outcomes.
BibTeX
@article{potestio2026patientlevel,
title = {{Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis)}},
author = {Luca Potestio and Salvatore Corrao and Luca Mastorino and Francesca Maria Gaiani and Emanuele Claudio Cozzani and Martina Maurelli and Nello Tommasino and Stefano Caccavale and Luigi Gargiulo and Carlo Giovanni Carrera and Lidia Sacchelli and Caterina Longo and Sara Marchetti and Alessandra Michelucci and Dario Valguarnera and Andrea Carugno and Simone Mozzato and Francesca Lussana and Lorenzo Mercadante and Luca Cangialosi and Francesco Messina and Eugenia Veronica Di Brizzi and Matteo Bianco and Salvatore Scibetta and Chiara Assorgi and Marco Campoli and Rosa Giuseppa Angileri and Annunziata Dattola and Emanuele Trovato and Maria Esposito and Nicola Zerbinati and Claudio Guarneri and Francesco Loconsole and Valentina Dini and Anna Campanati and Claudia Lasagni and Federico Bardazzi and Angelo Valerio Marzano and Massimo Travaglini and Alessandra Narcisi and Anna Balato and Matteo Megna and Giampiero Girolomoni and Martina Burlando and Piergiorgio Malagoli and Simone Ribero and Diego Orsini},
journal = {Dermatology and Therapy},
year = {2026},
month = sep,
doi = {10.1007/s13555-026-01925-5},
url = {https://doi.org/10.1007/s13555-026-01925-5},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis)
AU - Luca Potestio
AU - Salvatore Corrao
AU - Luca Mastorino
AU - Francesca Maria Gaiani
AU - Emanuele Claudio Cozzani
AU - Martina Maurelli
AU - Nello Tommasino
AU - Stefano Caccavale
AU - Luigi Gargiulo
AU - Carlo Giovanni Carrera
AU - Lidia Sacchelli
AU - Caterina Longo
AU - Sara Marchetti
AU - Alessandra Michelucci
AU - Dario Valguarnera
AU - Andrea Carugno
AU - Simone Mozzato
AU - Francesca Lussana
AU - Lorenzo Mercadante
AU - Luca Cangialosi
AU - Francesco Messina
AU - Eugenia Veronica Di Brizzi
AU - Matteo Bianco
AU - Salvatore Scibetta
AU - Chiara Assorgi
AU - Marco Campoli
AU - Rosa Giuseppa Angileri
AU - Annunziata Dattola
AU - Emanuele Trovato
AU - Maria Esposito
AU - Nicola Zerbinati
AU - Claudio Guarneri
AU - Francesco Loconsole
AU - Valentina Dini
AU - Anna Campanati
AU - Claudia Lasagni
AU - Federico Bardazzi
AU - Angelo Valerio Marzano
AU - Massimo Travaglini
AU - Alessandra Narcisi
AU - Anna Balato
AU - Matteo Megna
AU - Giampiero Girolomoni
AU - Martina Burlando
AU - Piergiorgio Malagoli
AU - Simone Ribero
AU - Diego Orsini
PY - 2026
DA - 2026/09/01
JO - Dermatology and Therapy
DO - 10.1007/s13555-026-01925-5
UR - https://doi.org/10.1007/s13555-026-01925-5
AB - Introduction: Conventional Psoriasis Area and Severity Index (PASI) response rates provide a cross-sectional assessment of treatment effectiveness but do not capture the speed, magnitude, and persistence of clinical improvement. This study evaluated the patient-level cumulative clinical benefit of brodalumab over 52 weeks in routine clinical practice. Methods: This multicentre, retrospective, observational study included adults with moderate-to-severe plaque psoriasis treated with brodalumab within the Italian Landscape Psoriasis database. The primary analysis included patients with PASI assessments at baseline and Weeks 16, 32, and 52. Individual percentage PASI improvement trajectories were integrated using the trapezoidal area under the curve and expressed as normalized cumulative clinical benefit and clearance-equivalent days. Baseline factors associated with cumulative benefit were assessed using multivariable median quantile regression. Results: Among 858 patients eligible for the 52-week analysis, 764 had complete longitudinal PASI data, and 645 were included in the multivariable analysis. Median PASI decreased from 14.7 at baseline to 0.0 at Weeks 16, 32, and 52. At Week 52, 93.1%, 86.1%, and 70.4% of patients achieved PASI 75, PASI 90, and PASI 100, respectively. Median normalized cumulative clinical benefit was 97.4% (interquartile range, 90.0–100.0), corresponding to 300.0 clearance-equivalent days (277.2–308.0). Palmoplantar involvement was independently associated with lower cumulative benefit (adjusted median difference, − 3.21 percentage points; 95% confidence interval, − 6.29 to − 0.87), whereas scalp or facial involvement was associated with modestly higher benefit (+ 1.39; 0.38–3.27). Longer psoriasis duration was associated with a small increase in cumulative benefit. Conclusion: Brodalumab provided rapid, deep, and sustained disease control over 52 weeks. Patient-level cumulative outcomes may complement conventional PASI response rates by capturing the overall longitudinal treatment benefit. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13555-026-01925-5.
SN - 2193-8210
SN - 2190-9172
ER -